ÂÜŔňÂŇÂ×

Dr. Hunter’s career has revolved around examining ways to make implantable medical devices “bioactive” and “smarter” leveraging technologies borrowed from other industries such as pharmaceutical coatings, surface modification and sensor technologies. As an inventor with over 200 patents and patent applications to his name, he has been involved in the invention and development of the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, and the Quill barbed wound closure device; combined these products have been used in over 40 million patients and recorded revenues exceeding $25 billion.

Previously, Dr. Hunter co-founded and served as President and Chief Executive Officer of Angiotech Pharmaceuticals (1992-2011). After founding the company while a medical student in 1992, he grew the company to become a profitable and diversified device company with over 1,400 employees, several thousand commercially available products, and 12 facilities in 5 countries. His latest venture, Canary Medical, utilizes implanted sensor, battery and transmission technology to create “smart” implanted medical devices that can “self-report” on function, activity, wear, complications and patient outcomes for up to 20 years.